AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn’s disease

PUBT · 3d ago
AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn’s disease
  • AbbVie filed with the EMA seeking approval for SKYRIZI subcutaneous induction in adults with moderately to severely active Crohn’s disease.
  • Submission backed by Phase 3 AFFIRM data; the drug already has EU approval for Crohn’s disease with IV induction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG34511) on August 27, 2026, and is solely responsible for the information contained therein.